Cellular Healing
How pressurized oxygen fuels neurological repair at the cellular level
Hyperbaric Oxygen Therapy
What is Hyperbaric Oxygen Therapy?
Hyperbaric oxygen therapy involves breathing 100% medical-grade oxygen inside a pressurized chamber at 1.3 to 2.0 atmospheres absolute (ATA). This increases dissolved oxygen in blood plasma by 10–15 times normal levels, delivering healing oxygen to tissues that compromised vasculature cannot reach through red blood cells alone.
The therapy is FDA-cleared for 14 conditions and has an expanding evidence base for neurological applications including traumatic brain injury, post-concussion syndrome, and autism spectrum disorder.
Sessions typically last 60–90 minutes. Protocols for neurological rehabilitation involve 40–80 sessions delivered over several weeks, leveraging the cumulative effect of repeated oxygen exposure on neural tissue repair and neuroplasticity.
How HBOT Works
Four interconnected mechanisms that drive neurological recovery
Increased Tissue Oxygenation
Breathing pure oxygen at pressures up to 2.0 atmospheres increases dissolved oxygen in plasma by 10–15x, reaching tissues that compromised vasculature cannot supply through red blood cells alone.
Enhanced Cerebral Blood Flow
HBOT reduces cerebral hypoperfusion — the inadequate blood flow to brain regions that underlies many neurological deficits. This restores metabolic function in dormant but viable neural tissue.
Neurogenesis & Angiogenesis
Repeated HBOT sessions stimulate the growth of new blood vessels (angiogenesis) and promote neural stem cell proliferation, facilitating neuronal development and repair.
Anti-Inflammatory Cascade
HBOT modulates the inflammatory response by reducing pro-inflammatory cytokines and oxidative stress, creating optimal conditions for tissue healing and neural recovery.
Clinical Evidence by Condition
Peer-reviewed research supporting HBOT for neurological conditions
Traumatic Brain Injury
Strong EvidenceMeta-analysis of 250 patients across 4 studies demonstrated significant improvements in general cognitive scores (p=0.003), memory (p<0.00001), attention (p<0.00001), executive function (p=0.002), and motor skills (p<0.00001).
Source: Neurology, 2024 — Systematic Review & Meta-Analysis
Autism Spectrum Disorder
Emerging EvidenceA 2025 systematic review and meta-analysis concluded HBOT can markedly alleviate core ASD symptoms in children and adolescents. Earlier RCTs showed improvements in overall functioning, receptive language, social interaction, and eye contact.
Source: Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2025
Chronic Mild TBI & Concussion
Strong EvidenceSeven randomized controlled trials and six prospective studies demonstrated significant improvement in cognitive function, post-concussion symptoms, and quality of life for chronic mild TBI patients.
Source: European Society for Medical Advancement, 2024 — Literature Review
Neurological Rehabilitation
Moderate EvidenceHBOT significantly reduced mortality across all acute and subacute TBI studies (9 RCTs, 1 meta-analysis, 2 prospective studies) and improved functional outcomes in neurological recovery.
Source: Multiple RCTs & Meta-Analyses, 2020–2024
The Access Gap in Southern Utah
Families with the greatest need have the fewest options
50%
of children with ASD in Utah frontier counties are missed for identification
0
HBOT providers in Washington County offering neurological rehabilitation protocols
300+
miles families currently drive to Austin, TX for comparable treatment
1 in 37
Utah children identified with ASD — many more undiagnosed in rural communities
Washington County, Utah is a federally designated medically underserved area. Families facing traumatic brain injuries, autism, and complex neurological conditions have historically had no local access to hyperbaric oxygen therapy. The Satori Living Foundation exists to change that — through grant-funded programs that eliminate financial and geographic barriers to care.
Safety Profile
HBOT has an established safety record across thousands of clinical applications. In pediatric studies for autism spectrum disorder, minimal adverse events have been reported, and the therapy is well-tolerated in children as young as two years old.
- FDA-cleared for 14 medical conditions with expanding off-label evidence
- Non-invasive, non-pharmaceutical intervention
- Well-tolerated in pediatric populations with minimal side effects
- Administered under clinical supervision with standardized protocols
- No known drug interactions — can complement existing treatment plans
Help Fund Access to HBOT
Your support brings hyperbaric oxygen therapy to families in Southern Utah who have been told there are no options. Every dollar funds real sessions for real families.